{"organizations": [], "uuid": "38a8ff7013c14ce2e3252207b701867c73d593d4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530643?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Celsus, Volution announce that post-merger co. Akari will raise $75mm through PIPE", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Celsus, Volution announce that post-merger co. Akari will raise $75mm through PIPE", "spam_score": 0.0, "site_type": "news", "published": "2015-08-20T02:40:00.000+03:00", "replies_count": 0, "uuid": "38a8ff7013c14ce2e3252207b701867c73d593d4"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530643?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Celsus, Volution announce that post-merger co. Akari will raise $75mm through PIPE", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": ["Akari"], "text": "Celsus , Volution announce that post-merger co. Akari will raise $75mm through PIPE Deal Date: Aug-01-2015 / Deal # 201530643 Executive Summary \nCelsus Therapeutics PLC entered into a $75mm (net $70mm) private placement agreement led by Deerfield and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management, and other investors. The financing is contingent upon the closing of Celsus' reverse merger with Volution Immuno Pharmaceuticals SA which will result in Celsus being renamed Akari Therapeutics PLC . Investors will buy ADSs (each representing 100 ordinary shares), the price of which will be detailed once the transaction closes.", "external_links": [], "published": "2015-08-20T02:40:00.000+03:00", "crawled": "2015-08-20T18:04:06.245+03:00", "highlightTitle": ""}